Cancer BiologyBlood AdvancesPeer-reviewed
PI3Kδ activation, IL6 over-expression, and CD37 loss cause resistance to the targeting of CD37-positive lymphomas with the antibody-drug conjugate naratuximab emtansine
Alberto J. Arribas, Sara Napoli, Eugenio Gaudio…·Francesco Bertoni
This paper identifies two resistance mechanisms to the CD37-targeting ADC naratuximab emtansine in lymphoma cell lines and suggests combination therapies to overcome resistance.
12 citations